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ABSTRACT  The liver is structurally and functionally heterogeneous and complex, and it accomplishes 
crucial functions for the organism. Its most remarkable potential is its capacity to regenerate after 
injury in order to maintain whole body homeostasis and guarantee the survival of the individual. 
Under normal conditions, liver regeneration (LR) is attributed to adult hepatocytes, the main cells in 
the liver which are able to proliferate in response to different stimuli or injuries. Nevertheless, when 
liver injury is severe and/or hepatocytes are prevented from proliferation, liver stem/progenitor 
cells (LS/PCs) participate directing LR to maintain liver mass and functions. Different mechanisms 
have been shown to guide this second line of LR, such as intrahepatic and extrahepatic liver pro-
genitor cells, as well as transdifferentiation processes between hepatocytes and other liver cells. 
For this reason, many efforts have been made  to elucidate the specific molecular mechanisms 
which orchestrate this process; this in turn would improve the prognosis and treatment of liver 
diseases. In this review, we revisit the fascinating process of LR, also with a short overview about 
liver development, the process from which arises the concept of LS/PCs participating in LR, and 
very important nowadays when considering cell therapy and tissue bioengineering for the treat-
ment of patients suffering from liver disease.  
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The liver has been shown to be a master central regulator of me-
tabolism and detoxification. Thus, it uncovers a major role control-
ling part of body homeostasis, and liver failure would constitute a 
major health problem if this function is not properly carried out by 
the liver. Understanding this complex organ from its development 
during embryogenesis until the development of a liver disease will 
permit to pomp out with new targeted therapies and tissue engineer-
ing technologies to avoid liver failure or to recover liver functions 
crucial for life. More interesting for this review is the special ability 
of the liver to regenerate after toxic insults, tissue damage or tissue 
loss. Liver transplant is the only curative treatment for end-stage 
liver disease, which is the consequence of many chronic hepatic 
diseases. For instance, patients with hepatocellular carcinoma 
(HCC), the most often primary liver cancer and the second lead-
ing cause of cancer-related mortality worldwide, undergo surgical 
resection. However, remnant liver can exhibit poor regenerative 
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capacity because of the underlying pathologies. These cases of 
a defective process explain the huge interest to better understand 
the machinery of liver regeneration to find new biomarkers that 
could predict the response and to develop improved therapeutic 
options for patients with liver diseases. 
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The origin: an overview of liver development
To better understand the origin of this organ, it is worthy to start 
emphasizing its importance within the organism. The liver carries out 
numerous functions: glycogen storage, drug detoxification, plasma 
proteins secretion (Albumin (ALB), Transferrin and Apolipoproteins) 
and, importantly, the control of metabolism (glucose, fatty acids 
and triglycerides, cholesterol, urea and non-essential amino acids). 
Although hepatocytes account for about 80% of liver weight, other 
biologically important cell types are present: Biliary Epithelial Cells 
(BECs or cholangiocytes), Sinusoidal Endothelial Cells (SECs), 
Kupffer cells (KCs, resident liver macrophages), Pit cells (resident 
liver natural killer cells) and Hepatic Stellate Cells (HSCs) (Si-Tayeb 
et al., 2010).
Liver development in the embryo occurs in several stages (Fig. 
1). In general terms, first, cells become “competent” and can restrict 
their fate. Then, competent cells subsequently become “committed” 
to a specific lineage, exhibiting morphological changes and express-
ing genes associated with cell commitment. Eventually, cells then 
“differentiate” along that lineage and are ultimately able to carry out 
the function of a terminally differentiated cell (Hata et al., 2007). 
In mice, at early stages of development, epithelial cells of the 
foregut endoderm express the transcription factors (TFs) Foxa1/2 
and Gata4-6, which permit to establish the “competence” of these 
cells to develop into the liver. At E8.5, this “competent” foregut 
endoderm interacts with the cardiac mesoderm and “commit” to 
induce hepatic fate in the ventral foregut endoderm. This is due to 
the coordinated signaling of Fibroblast Growth Factors (FGFs) from 
the cardiac mesoderm, and Bone Morphogenetic Proteins (BMPs) 
from the septum transversum mesenchyme (STM) that facilitate the 
“commitment” of “competent” foregut endoderm cells to become 
hepatoblasts. On the contrary, Wnt/b-catenin signaling appears to 
repress liver fate (Rossi et al., 2001; Zorn, 2008; Kung et al., 2010; 
Si-Tayeb et al., 2010). 
Shortly after hepatic specification (E8.5 to E9), the epithelium 
begins to express liver genes such as Alb, a-fetoprotein (Afp), 
transthyretin (Ttr), Hnf1a  and high expression of Cytokeratins (CKs) 

















































































Fig. 1. Schematic overview of murine liver development. Stages of liver development are depicted, from a macroscopic and molecular point of 
view. Important factors are represented in each step. See text for further details.
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epithelium thickens finally forming the liver diverticulum. Between E9 
to E9.5, the basal layer surrounding the hepatic endoderm breaks 
down and hepatoblasts delaminate from the epithelium, migrate 
to invade the adjacent STM and continue to proliferate and differ-
entiate, to give rise the nascent liver bud. Several TFs and signals 
from endothelial cells are required for this process, such as Hhex, 
Gata4-6, Prox1, Onecut-1 (OC-1, also known as Hnf6) and Onecut-2 
(OC-2) (Shafritz and Dabeva, 2002; Zorn, 2008; Kung et al., 2010; 
Si-Tayeb et al., 2010) (Fig. 1).
Between E10-15, the liver bud undergoes a period of acceler-
ated growth and it is colonized by hematopoietic cells to become 
the major fetal hematopoietic organ. This is regulated by paracrine 
signals from STM and hepatic mesenchyme that promote prolifera-
tion and survival, including FGF, BMP, Hepatocyte Growth Factor 
(HGF), Transforming Growth Factor-beta (TGF-b), retinoic acid 
(RA) and Wnt, the last having the opposite effect than in previous 
stages. Around E14, one of the major stages occurs, when these 
bipotential hepatoblasts “differentiate” into hepatocytes and chol-
angiocytes. Initially, hepatoblasts express genes associated with 
both adult hepatocytes (Hnf4a, Alb, CK-8/18) and BECs (CK-19), 
as well as fetal liver genes such as Afp. Those hepatoblasts resid-
ing next to portal veins adopt a specific structure together with the 
expression of BDS7, an increase in CK-19 and BEC TFs (OC-1/2 
and HNF1b), concomitant with downregulation of hepatic genes, 
finally becoming cholangiocytes. Among the mesenchyme signals 
involved, it is found TGF-b and Jagged-Notch, which stimulates the 
expression of EGF, and together with HGF, participate in the dif-
ferentiation towards a biliary epithelial phenotype. On the contrary, 
most hepatoblasts localized in the liver parenchyma differentiate into 
hepatocytes, acquiring characteristics of epithelial cells arranged 
in hepatic chords, and expressing Alb and CK-8/18. Signals such 
as oncostatin M (OSM), glucocorticoids, HGF and Wnt promote 
hepatocyte differentiation, most of them through the regulation of 
the TFs C/EBPa, Hnf1a and Hnf4a. Maturation into hepatocytes 
and cholangiocytes continue until several weeks after birth. At this 
point, the organ’s main function switches from hematopoiesis to 
metabolism, a capacity that dominates in the adult liver (Fig. 1) 
(Shafritz and Dabeva, 2002; Hata et al., 2007; Zorn, 2008; Kung et 
al., 2010; Gordillo et al., 2015).
Liver regeneration: a well studied and still unknown 
process
Although function, structure and development clearly differentiate 
the liver from other organs, the outstanding physiological charac-
teristic that makes it special is the unique ability to fully regenerate. 
This process reminds the ancient greek myth of Prometheus, a titan 
who was bond to the mountain Caucasus by Zeus to get his liver 
eaten by an eagle daily, which regenerated during the nights, as a 
punishment for stealing the fire from gods and giving it to the mankind. 
Liver regeneration (LR) is the development of new hepatocytes dur-
ing adulthood. Adult hepatocytes can replicate in a highly-regulated 
manner, regenerating the liver in response to surgical ablation, toxic 
injury, infections, exogenous stimulus, massive hepatocyte necrosis 
or apoptosis. In this section, we will try to give a vast overview of LR. 
Experimental models of liver regeneration (LR)
Several models, considering animal species and methodologies, 
have been proposed for the study of LR. On the one hand, among 
the animal models traditionally used, rodents (rats and mice) are 
on the top, and almost all the studies and the current knowledge 
about LR come from them (Forbes and Newsome, 2016). However, 
new animal models have recently emerged, such as zebrafish. On 
the other hand, several methods have been described to induce 
loss of liver mass. It can be induced in pharmacological models by 
administering hepatotoxic chemicals (carbon tetrachloride (CCl4), 
D-galactosamine or acetaminophen), bacterial particles (lipopolysac-
charides (LPS)) and virus, among others. But there are also surgical 
models, and the most commonly and best-studied is the surgical 
procedure which removes 70% of the liver mass in rodents, known 
as 2/3 partial hepatectomy (PHx), and first described by Higgins 
and Anderson (Higgins and Anderson, 1931). Taking advantage of 
the multi-lobe structure of the liver, three of the five lobes (left lateral 
and median lobes) are removed by an easy surgical procedure, 
causing minimal tissue damage to the residual two lobes, which 
grow in size to restore the mass. The process, in rats and mice, is 
almost complete within 7-14 days after surgery. 
What is the reason for regeneration?
The words “liver regeneration” could indicate that the liver is able 
to recover exactly the same disappeared lobules after resection. 
Nevertheless, this process is actually a “compensatory hyperplasia 
and hypertrophy” rather than a true restoration of the liver’s original 
gross anatomy and architecture, which takes place in amphibians 
or Salamander in some parts of their bodies. Thus, during liver “re-
generation” after PHx, the excised parts do not grow back. Instead, 
the remaining liver increases the mass to compensate for the lost 
tissue. Regarding terminology, hyperplasia would account for an 
increase in cell number, while hypertrophy refers to an increase in 
cell size. Although it has been generally accepted that hepatocytes 
undergo one to two rounds of cell division after PHx, several stud-
ies point to the hypertrophy of hepatocytes during LR (Nagy et al., 
2001; Minamishima et al., 2002; Miyaoka et al., 2012). 
The reason of this special process is that liver functions are 
extremely essential for survival of the organism. Liver mass is 
maintained within a very narrow range in relation to the overall 
body mass, known as Liver Index (liver weight/body weight) x100 ~ 
4-5%). The liver-to-body-weight ratio must be maintained always at 
100% of what it is necessary for body homeostasis, so the degree 
of grow is precisely controlled. If there is loss or gain of liver mass, 
such as after liver injury or pregnancy, respectively, compensatory 
proliferation or apoptosis of cells restore this ratio once the stimu-
lus is removed (Riehle et al., 2011; Kang et al., 2012; Cienfuegos 
et al., 2014). This unique relationship is termed “hepatostat”, and 
it has been well-defined and studied by many groups (Avila and 
Moschetta, 2015; Naugler et al., 2015) and recently extensively 
reviewed (Michalopoulos, 2017). Therefore, liver homeostasis is 
of huge importance for the organism to survive, and “hepatostat” 
permits to drive LR, to control its termination up to a right liver size, 
as well as to maintain the liver weight even under normal physi-
ological conditions.
First line of liver regeneration: hepatocytes as the main player
It is now well accepted that two physiological forms of LR exist 
in response to different types of liver injury. The first one, in the 
case of PHx and some chemical liver injuries, is when liver mass 
is replaced by replication of existing hepatocytes, considered the 
quickest and most efficient way of LR.
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Mainly three networks mediate LR after PHx: cytokines, growth 
factors (GFs) and metabolic signals. Due to the high redundancy 
among their intracellular components, loss of an individual gene 
rarely leads to complete inhibition of LR. It proceeds along sequen-
tial and overlapping steps: an initiation “priming phase”, rendering 
hepatocytes in a replicative competence state; a “proliferation/
progression phase”, with the expansion of the entire hepatocyte 
population; and a “termination phase”, where cell proliferation 
is suppressed to terminate regeneration at a defined point (Fig. 
2). In addition, proliferation in the expansion phase requires a 
complex re-design of the liver, a remodeling process represent-
ing a “fourth phase”.
Priming phase
Hepatocytes resting in proliferative quiescence (G0 phase) can 
rapidly and synchronously enter into cell cycle upon stimulation, 
undergoing one to two rounds of replication before returning to 
quiescence. However, in quiescent state, hepatocytes do not fully 
respond to GFs and need to be “primed” to enter the cell cycle 
(G1 phase). The cytokine network acts as the “priming phase”, 
which occurs during the first 4h and begins with the recognition 
of the Pathogen-Associated Molecular Patters (PAMPs) and the 
Damage-Associated Molecular Patterns (DAMPs) released from 
necrotic cells after tissue injury. They trigger the natural immune 
response, Tumor Necrosis Factor-alpha (TNF-a) secretion by KCs, 
and interleukins IL-6, IL-1b and IL-8 synthesis. In brief, there is 
an initial activation of Nuclear Factor-kappa B (NF-κB) in KCs via 
TNF, lymphotoxin (from T cells), and/or complement components, 
with downstream secretion of IL-6. In turn, IL-6 binds its receptor 
on hepatocytes, leading to activation of the TF Signal Transducer 
and Activator of Transcription 3 (STAT3), among other pathways. 
Then, several immediate-early genes related to hepatocyte pro-
liferation are induced within 2h, such as c-Fos, c-Jun and others 
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Fig. 2. Liver regeneration based on hepatocyte proliferation. Four phases are represented: Priming, Proliferation/progression, Termination and 
Matrix remodeling. Cytokines, growth factors and metabolic signals involved are also indicated. See text for further details.
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Although these cytokines are not directly mitogenic to hepatocytes, 
they are crucial to orchestrate and optimize the process: delayed 
LR was observed in TNFR1-/- mice due to inefficient activation of 
NF-κB (Yamada et al., 1998) and in mice lacking IL-6 due to loss 
of STAT3 activation (Cressman et al., 1996).
Proliferation/progression phase
After cytokines have triggered the G0/G1 transition, cell cycle 
progression is driven by GFs, which override the G1 restriction 
point denominated “R”, allowing hepatocytes enter S phase (DNA 
synthesis) 24 and 36h post-PHx in rat and mouse, respectively. 
After, hepatocytes enter into mitosis 48h post-PHx. The mitogenic 
GFs Epidermal Growth Factor (EGF) and HGF activate their re-
spective receptors, EGF Receptor (EGFR) and c-Met, stimulating 
hepatocytes progression through the cell cycle. Both are tyrosine 
kinase receptors, able to activate multiple intracellular signaling 
pathways. Among them, Mitogen-Activated Protein Kinase (MAPK), 
STAT3, Phosphatidylinositol-3-Kinase (PI3K)/Akt and Extracellular 
signal-Regulated Kinase 1 and 2 (ERK1/2) are the most important 
for LR, which in turn regulate a multitude of TFs including c-Jun, 
c-Fos, c-Myc, NF-κB, STAT3 and C/EBPb. Together with the induc-
tion of intermediate and early-delayed genes, such as cyclins and 
Cyclin Dependent Kinases (CDKs), they facilitate the transition to 
DNA synthesis and mitosis (Riehle et al., 2011; Kang et al., 2012; 
Mao et al., 2014; Cienfuegos et al., 2014). Finally, FGF family is 
also implicated in LR. Models expressing a dominant-negative 
mutant of FGF receptors (FGFR) signaling pathways presented 
delayed proliferation after PHx (Steiling et al., 2003). However, not 
all FGFRs play the same role: while loss of FGFR4 in mice did not 
affect the process (Yu et al., 2000), lacking FGFR1 and FGFR2 
provoked an increased mortality showing a cytoprotective role of 
these receptors in regenerating liver (Böhm et al., 2010).
However, c-Met and EGFR are key factors in LR, which deserve 
a detailed discussion.
HGF/c-Met pathway - The receptor c-Met is activated by the 
mitogen HGF, produced by non-parenchymal cells, such as HSCs 
and SECs. It is produced by HSCs as single peptide (pro-HGF) and 
deposited in the extracellular matrix (ECM). Interestingly, one of the 
earliest changes is the increase in the activity of Urokinase-type 
Plasminogen Activator (uPA) within 1min after PHx. uPA mediates 
the ECM remodeling that takes place soon after PHx, involving 
metalloproteinases (MMPs) activation, such as MMP-2 and MMP-9 
(Kim et al., 2000). Then after, there is the subsequent activation 
of this pro-HGF, finally releasing active HGF in the environment of 
hepatocytes as well as in blood circulation. In fact, uPA deficiency 
has been shown to retard LR (Shimizu et al., 2001). 
EGFR pathway - This receptor is activated through different 
sources: in an autocrine manner by Amphiregulin (AR) and Trans-
forming Growth Factor-alpha (TGF-a); by Heparin Binding EGF-like 
growth factor (HB-EGF) derived from KCs and SECs; and by EGF, 
secreted from salivary glands and Brunner’s glands in the duodenum 
(Berasain and Avila, 2014). EGFR ligands have different but often 
overlapping functions during LR. Thus, TGF-a null mice have no 
deficiency during LR (Russell et al., 1996), whereas the removal 
of the submandibular glands in mice (source of EGF) or AR and 
HB-EGF knock-out mice promoted an impaired or delayed LR 
(Noguchi et al., 1991; Berasain et al., 2005; Mitchell et al., 2005). 
It seems that both receptors have unique and potentially overlap-
ping functions. Many studies have been done to better understand 
their role during LR. First studies were based on mice lacking c-Met 
in the liver. On the one hand, inducible deletion of the c-Met gene 
in the liver caused a defective exit of hepatocytes from quiescence 
and a delay in cell cycle entry after PHx (Borowiak et al., 2004). 
On the other hand, deletion of the c-Met gene in hepatocytes in 
a non-inducible manner showed the inability of these animals to 
survive the procedure showing severe necrosis (Huh et al., 2004). 
Subsequent and complementary studies based on RNA interference 
(shRNA) against c-Met and HGF in rats supported the previous 
works (Paranjpe et al., 2007). Moreover, a more recent work also 
showed a regenerative defect in hepatocyte-specific Met KO mice. 
Specifically, after PHx, Met-deficient hepatocytes showed a block 
in early/mid G2 phase and consequently, a failure in G2/M gene 
expression program. Similar alterations were found in primary he-
patocytes from unchallenged Met KO mice, which could be partially 
reversed by treating the cells with EGF (Factor et al., 2010). All 
these works confirmed the importance of c-Met in LR. Regarding 
EGFR pathway, to overcome the problem of redundancy among 
ligands, models lacking EGFR in hepatocytes were generated. 
The first study based on the genetic loss of EGFR in mice showed 
higher rates of mortality post-PHx. However, apoptosis was not 
increased, suggesting that activation of the EGFR pathway was 
not directly related with survival signals for hepatocytes. Moreover, 
delayed and reduced hepatocyte proliferation was observed in the 
remaining animals, although complete regeneration occurred, so 
EGFR would be important but not essential for LR (Natarajan et 
al., 2007). Another study using interference RNA in rats confirmed 
the critical role of this pathway, observing decreased DNA replica-
tion after PHx, concomitant with an up-regulation of Met and other 
ErbB members and, finally, liver restoration occurred (Paranjpe et 
al., 2010). In contrast to these two studies, animals treated with 
a neutralizing antibody against EGFR did not present altered LR 
(Van Buren et al., 2008). More recently, a different study also us-
ing EGFR null mice showed delayed cell cycle progression and 
proliferation after PHx, but the overall effect on liver regeneration 
was relatively minimal. Additionally, after CCl4-induced injury only 
the Met-KO, but not the EGFR-KO, displayed enhanced necrosis 
and delayed LR, effects that were more prominent in the EGFR-
Met double KOs, suggesting that EGFR, and at a greater extent 
Met, may partially compensate each other (Scheving et al., 2015). 
Regarding this issue, our group has recently developed a novel 
transgenic mouse model expressing a hepatocyte-specific truncated 
form of human EGFR, lacking the catalytic domain, thus acting as 
a negative dominant mutant (aEGFR) allowing definition of its tyro-
sine kinase-dependent functions. These animals displayed lower 
and delayed proliferation as well as lower activation of proliferative 
early signals after PHx, demonstrating a critical role during the 
initial phases of LR. Moreover, it correlated with an overactivation 
of the TGF-b pathway, and subsequent amplification of its cyto-
static effects. Nevertheless, NEGFR were able to fully regenerate 
the liver by overactivating compensatory signals, such as c-Met 
pathway (López-Luque et al., 2016). Regarding this issue, a very 
recent work has demonstrated that only the combined elimination 
of Met and the inhibition of the EGFR signaling pathway completely 
abolishes LR. They state that both pathways separately control 
many non-overlapping critical points, and inhibition of only one of 
them had distinct alterations in different signaling pathways, al-
lowing for compensation when only one of the signals is blocked 
(Paranjpe et al., 2016). All these works emphasize the requirement 
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of simultaneous co-activation of parallel signaling pathways for full 
mitogenic signaling and efficient LR.
It is important to mention that, after PHx, metabolic alterations 
occur in the remnant liver. The liver must continue regulating systemic 
energy levels while meeting its own demands for nucleotide and 
protein synthesis needed for cell division. Thus, translation is the 
control point that integrates nutrient levels with mitogenic signals 
and most proteins involved are downstream of mammalian target 
of rapamycin (mTOR). Almost a complete loss of hepatocyte DNA 
replication was observed in S6 KO mice after PHx (Volarevic et al., 
2000). Importantly, changes in lipid and glucose metabolism are 
observed. A regenerative transient steatosis is evident during LR 
after PHx at early stages, which is necessary for LR (Huang and 
Rudnick, 2014) and concomitant with upregulation of genes related 
to the adipogenic program (Shteyer et al., 2004). Increased de novo 
hepatic fatty acid production and catabolism of systemic adipose 
tissue might be the main sources of the lipid that accumulates in 
the regenerating liver. It is required to meet the increased energy 
demand for rapid cell proliferation and essential for the enhanced 
biosynthesis of membrane phospholipids (Rudnick and Davidson, 
2012). Disruption of hepatic adipogenesis and lipid accumulation 
is associated with impaired or inefficient LR following PHx (Shteyer 
et al., 2004; Kohjima et al., 2013). Interestingly, EGFR plays a role 
in the regulation of liver and plasma lipid levels in adult male mice 
(Scheving et al., 2014). In addition, recently it has been shown 
that EGFR, but not the HGF/c-Met pathway, is required for fat 
accumulation and properly regulation of key enzymes related to 
the de novo lipid synthesis during LR, revealing a new function 
for EGFR kinase activity which is not overlapping with the HGF/c-
Met pathway (López-Luque et al., 2016; Paranjpe et al., 2016). 
Regarding glucose metabolism, mice develop hypoglycemia soon 
after PHx, showing insulin decreased levels. To compensate this, 
many TFs are activated upregulating glucose metabolism. Stud-
ies postponing this hypoglycemic response delayed LR (Huang et 
al., 2016). Finally, bile acid metabolism is also altered, increasing 
twice their amounts per liver mass without showing hepatotoxicity 
(Csanaky et al., 2009).
Termination phase
The initial burst of hepatocyte proliferative activity is followed 
by secondary waves of mitosis until original liver mass is restored. 
However, growth must be finished to control liver size and homeo-
stais, although the precise mechanisms of a proper termination 
are still very poorly understood, and even controversial. Generally, 
when the regenerating liver reaches certain size, several factors 
promote proliferation arrest. Surprisingly, many of them are also 
present in the first stages of LR. It has been proposed that these 
factors would act as a “brake”, controlling the speed of proliferation 
and the terminal point of the process, and even ensuring the right 
direction, preventing oncogenesis. An extensive review focused in 
the termination phase has been recently published (Liu and Chen, 
2017). For this reason, this phase is as important as the previous 
ones, and more studies should be performed to decipher its molecular 
mechanisms. It is known that it involves multiple factors, including 
TGF-b family (TGF-b1, activins), IL-1, and tumor suppressor genes 
(p53, p21) (Michalopoulos, 2010). 
TGF-b1 is a known suppressor of hepatocyte proliferation and 
inducer of apoptosis. Then, it would be easy to think a role for it at 
the end of LR. Surprisingly, its expression increases rapidly after 
PHx, and levels are maintained until termination of the process 
(Braun et al., 1988). In addition, TGF-b plasma levels rise together 
with HGF, suggesting that the cytokine is released after the re-
modeling of the ECM, where it is bound to decorin (Dudás et al., 
2001). However, responsiveness to this factor declines transiently 
in the regenerating liver. TGF-b inhibitory effects are surpassed by 
different mechanisms: TGF-b receptors downregulation (Chari et 
al., 1995), increasing the transcriptional repressors SnoN and Ski 
(Macias-Silva et al., 2002), as well as being removed and inactivated 
through binding a-2-macroglobulin in the circulation (LaMarre et 
al., 1991). Moreover, regenerating hepatocytes showed a reduced 
response to TGF-b cytostatic and cytotoxic effects, through up-
regulation of anti-apoptotic and anti-oxidant signals (Herrera et 
al., 2004). Interestingly, mice lacking the type II TGF-b receptor in 
hepatocytes presented an increased proliferative response after 
PHx, but hyperproliferation was transient and normal regeneration 
was achieved (Romero-Gallo et al., 2005). Thus, although initially 
it was supposed that TGF-b could play a relevant role in mediating 
termination of LR, more recent results indicate that it is not neces-
sary during this stage. Higher and accelerated DNA synthesis peak 
after PHx was found in a Tgfbr2 knockout animal model. Neverthe-
less, similarly to the previous mentioned work, a normal ending of 
LR occurred, associated with increased compensatory inhibitory 
signals, particularly Activin A (Oe et al., 2004). Interestingly, TGF-b 
could play an essential role in the first stages of LR, as transgenic 
mice expressing  EGFR form presented an overactivation of the 
TGF-b pathway leading to a delayed regeneration (López-Luque et 
al., 2016). Thus, a perfect spatio-temporal orchestration of TGF-b 
signaling during the process is required, although it is still unclear. 
As the NADPH oxidase NOX4 is known to mediate TGF-b-induced 
apoptosis (Carmona-Cuenca et al., 2008) and to inhibit hepatocyte 
proliferation (Crosas-Molist et al., 2014), it would be a perfect can-
didate for mediating some of the TGF-b suppressor actions during 
LR. Interestingly, NOX4 has been shown to be also regulated during 
LR, decreasing its levels soon after PHx and recuperating them at 
the end of the process (Crosas-Molist et al., 2014). This should be 
an additional mechanism to avoid TGF-b suppressor effects during 
the early liver regenerative process.
Among other players linked to the termination phase, the Integ-
rin Linked Kinase (ILK) would play a role. ILK is under the plasma 
membrane associated with b1 integrin, suppressing hepatocyte 
growth. ILK hepatoespecific KO animals acquire hepatomegaly and 
enhanced hepatocyte proliferation, presenting an impaired termina-
tion of the process (Gkretsi et al., 2008). On the other hand, Glypican 
3, a GPI-linked protein on hepatocytes plasma membrane, has been 
shown to suppress proliferation after PHx when overexpressed in 
transgenic animals (Liu et al., 2010). In addition, these animals also 
presented decreased expression of Yap (Yes-associated protein), 
controlled by the Hippo pathway, and which has been considered 
a central player controlling cell size and, finally, liver hepatostat.
Thus, a proper balance of all these signals during the different 
phases might be a good determinant of the efficacy of LR.
Second line of liver regeneration: the time for 
stem/progenitor cells
When the liver is damaged with specific chemicals, when injury 
is severe, or when mature hepatocytes are prevented from prolif-
eration, the contribution of liver stem/progenitor cells (LS/PCs) is 
crucial for LR success (Fig. 3).
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As it has been mentioned, during liver development, both he-
patocytes and BECs originate from the common precursor named 
hepatoblast. It is suggested that combined hepatocyte loss con-
comitant with impaired hepatocyte proliferation is necessary to 
activate these LS/PCs during LR. This has been observed in models 
combining PHx with chemical inhibition of hepatocyte proliferation 
using 2-acetylaminofluorene (2-AAF) or retrorsine in rats, or a 
choline-deficient diet in mice (Liu et al., 2016). LS/PCs reside in the 
transition region between the canaliculi and intrahepatic bile ducts, 
named Canal of Hering. It has been postulated that LS/PCs can 
be characterized by a positive staining for BEC markers, but also 
by the appearance of LS/PCs (named “oval cells” in rodents and 
“ductular structures” in humans) throughout the parenchyma when 
there is a liver repair process, often forming clusters of duct-like and/
or cord-like structures (Itoh, 2016). Therefore, in an elegant review, 
Itoh propose a model for homeostatic maintenance and LR, where 
the scenario starts with hepatocyte proliferation upon acute or mild 
hepatocyte injury. However, if injury is severe or chronic, a novel 
epithelial cell population identified by Font-Burgada et al., namely 
the periportal Hybrid hepatocytes (HybHPs), is activated, located 
in the portal triads of healthy livers and expressing low amounts 
of Sox9 and other bile-duct-enriched genes (Font-Burgada et 
al., 2015). If they are selectively damaged, then a recently found 
population of “unipotent stem cell-like“ hepatocytes with self-
renewing abilities adjacent to the central vein (generally diploid 
and expressing Axin2, the canonical Wnt signaling target gene) 
can participate (Wang et al., 2015). Finally, if all these cells fail, it 
is when LS/PCs in the biliary compartment become activated to 
re-establish the parenchyma (Itoh, 2016) (Fig. 3).
The response of LS/PCs includes activation, proliferation, 
LS/PCs proliferation. They comprise inflammatory cytokines (IL-6, 
TNF-a, Stromal Derived Factor (SDF-1), TNF-like weak inducer 
of apoptosis (TWEAK), Stem Cell Factor (SCF), etc.), regulatory 
proteins (such as MERLIN acting on EGFR), or other paracrine 
messengers from neighboring mesenchymal cells (HGF, FGF and 
TGF-a/b). Specifically, HGF, EGF, TGF-a and SCF stimulate LS/
PCs proliferation. On the contrary, TWEAK/Fibronectin 14 would 
participate in the activation, and SDF-1/CXC receptor 4 (SDF-1/
CXCR4) axis in the migration of these cells (Liu et al., 2016). Among 
all these factors, as during LR from pre-existing hepatocytes, c-
Met and EGFR pathways are essential for regeneration from LS/
PCs. In this sense, Met signaling is essential for survival of oval 
cells in vitro, as its deletion increases sensitivity to TGF-b-induced 
apoptosis, through the activation of the PI3K signaling pathway 
(del Castillo et al., 2008a; Martínez-Palacián et al., 2013). More-
over, c-Met pathway promotes oval cell migration in vitro, activity 
that also involves PI3K signaling (Suárez-Causado et al., 2015). 
In vivo, lack of c-Met has profound effects on the LS/PCs-driven 
regeneration, including impairment in cell proliferation, migration 
and differentiation into hepatocytes (Ishikawa et al., 2012). Re-
garding EGFR, it also promotes oval cell proliferation and survival, 
although it is dispensable for c-Met-mediated proliferation and 
survival of these cells, functioning independently one from each 
other (Martínez-Palacián et al., 2012). Interestingly, while c-Met 
is important for hepatocytic differentiation, EGFR promotes chol-
angiocyte specification concomitantly suppressing hepatocyte 
commitment inducing Notch1 (Kitade et al., 2013). Therefore, 
it is very common to find that these factors play different, and 
sometime opposite, roles on hepatocytes and progenitors cells. 
Finally, all the above-mentioned GFs and cytokines trigger mul-

























Fig. 3. Liver regeneration based on 
stem/progenitor cells. Intrahepatic 
and extrahepatic liver progenitor cells 
participate in regenerating the liver 
when hepatocytes are prevented from 
proliferating or when injury is severe. 
See text for further details.
migration and differentiation, 
finally leading to hepatocytes or 
cholangiocytes. Parenchymal 
and non-parenchymal cells in the 
liver, the ECM, GFs and signaling 
pathways participate contributing to 
LS/PCs niche during LR. Regard-
ing the crosstalk with other cells, 
for instance, it is found that HSCs 
participate in the first stages of LR 
producing HGF, promoting prolif-
eration in LS/PCs. However, at the 
end of the process, high levels of 
TGF-b produced also by HSCs sup-
pressed DNA synthesis in the same 
cells, revealing a dual role for HSCs 
in LS/PCs-mediated proliferation 
(Chen et al., 2012). Regarding 
the ECM, its remodeling by MMPs 
and the multiple factors found in it 
have been reported to stimulate 
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tiple signaling pathways. For instance, activation of NF-κB and 
STAT3 in rat oval cells is required for their activation, expansion 
and differentiation (Sánchez et al., 2004). Finally, Wnt and Notch 
pathways participate with opposite roles: while the former direct 
LS/PCs towards the hepatocytic fate, the second promotes their 
differentiation towards the biliary lineage (Boulter et al., 2012). Of 
special relevance is also the implication of inflammatory signals 
and cells, known as “inflammatory niche”, on the regeneration by 
progenitor cells. Although some of them have been mentioned 
just above, it is worthy to point out that many of them play con-
trary roles in the regeneration from mature hepatocytes and the 
one carried out by progenitor cells. For instance, while IFN-g 
signaling appears to have a negative impact on LR by mature 
cells, the effects of this inflammatory cytokine on the progenitor 
cell compartment appear very different (Bisgaard et al., 1999). 
However, what it is completely obvious is that the inflammatory 
microenvironment regulates liver progenitor cells expansion and 
fate, which has been extensively reviewed by others (Santoni-
Rugiu et al., 2005).
However, the huge controversial discussion comes up with the 
hypothesis that hepatocytes and cholangiocytes would be liver 
progenitors cells per se when undergoing transdifferentiation 
from one cell type to the other, acting as “facultative stem cells” 
(Michalopoulos and Khan, 2015). Many different studies have 
been focused on the possibility that cholangiocytes become LS/
PCs to rescue hepatocytes. While most of them confirmed this 
hypothesis (Golding et al., 1995; Huch et al., 2015; Raven et al., 
2017), other groups did not (Schaub et al., 2014; Yanger et al., 
2014). Almost all these studies prove that some cholangiocytes 
express hepatocyte-associated TFs, then proliferate as LS/PCs 
and, finally, become hepatocytes. Less controversy is found 
about the capacity of hepatocytes transdifferentiating directly to 
cholangiocytes. This has been observed in rats after biliary injury, 
without evidence of formation of LS/PCs (Michalopoulos et al., 
2005) (Fig. 3). However, various works point to the capacity of 
hepatocytes to acquire also stem cell properties. Thus, after TGF-
b treatment, the subpopulation of rat fetal hepatocytes (FH) that 
survive to its apoptotic effects undergo epithelial-to-mesenchymal 
transition (EMT), expressing high levels of mesenchymal mark-
ers and lacking epithelial and differentiation ones, concomitant 
with expression of progenitor markers. Moreover, they acquire 
resistance to TGF-b-induced apoptosis (Valdés et al., 2002; del 
Castillo et al., 2006). Their isolation and characterization dem-
onstrated that they behave as liver progenitors, supporting the 
hypothesis that hepatocytes can function as facultative liver stem 
cells and that TGF-b might play an essential role in this trans-
differentiation process (del Castillo et al., 2008b). Importantly, 
this response was observe in human hepatocytes (Caja et al., 
2011), reaffirming TGF-b as an inducer of EMT and promoting 
the acquisition of a stem-like phenotype. Interestingly, this was 
a reversible process, where mesenchymal stem-like cells were 
able to re-differentiate to hepatocytes, fact that opens feasible 
possibilities for human liver diseases.
Nevertheless, not only resident LS/PCs play a role in this second 
line of LR. Nowadays, there is a consensus that also stem cells 
from extrahepatic sites, in particular the bone marrow (BM), can 
participate and contribute to LR (Petersen et al., 1999; Theise et 
al., 2000) although with low efficiency. Hematopoietic Stem Cells 
(HSCs) and Mesenchymal Stem Cells (MSCs) are among the most 
well defined ones, migrating to the injured liver through circula-
tion to regenerate the organ (Fig. 3). The differentiation of MSCs 
into MSCs-derived hepatocytes (MDHs) arises with 3 important 
shifts: morphologically (changing from a fibroblast-morphology to 
a polygonal-epithelial shape), phenotipically (regarding several 
TFs) and functional (acquiring the ability for glycogen storage, 
detoxification and lipid metabolism, within others). Nevertheless, 
the mechanisms of MSCs and HSCs transdifferentiation to he-
patocytes are controversial. In fact, cell fusion with hepatocytes 
is an alternative way by which both cell types can achieve the 
plasticity required to develop into hepatocytes (Vassilopoulos et 
al., 2003; Wang et al., 2003; Quintana-Bustamante et al., 2006; 
Liu et al., 2015). 
Finally, considering both mechanisms of the liver to regenerate, 
it seems obvious that progenitor cells can be a very reasonable 
option and an attractive alternative to organ transplantation due 
to several benefits: they can be expanded in culture without 
losing bidirectional differentiation potential, and an autologous 
transplant after LS/PCs isolation from a patient would obviate the 
need for immunosuppression (Liu et al., 2016). Several alterna-
tive candidates to liver transplants have been proposed based 
on the progenitor cells concept, including the above-mentioned 
MSCs and, more recently, induced pluripotent stem cells (iPSCs).
The attractive ability to derive pluripotent cells from adult 
human tissues opens new opportunities in research and, impor-
tantly, in therapy. This direct reprogramming towards producing 
pluripotent stem cells was first achieved and published in 2007 
(Takahashi et al., 2007; Yu et al., 2007). With this in mind, several 
works have developed the technology in the liver field. Thus, 
iPSCs-derived hepatocytes proved to have functional and prolif-
erative capabilities needed for LR in vivo in mice (Espejel et al., 
2010), and this could be induced modeling the embryonic liver 
development conditions (Sancho-Bru et al., 2011). Later, a great 
achievement was carried out by Takebe et al., with the formation 
of vascularized and functional human liver after transplantation 
of liver buds created in vitro derived form iPSCs (Takebe et al., 
2013). This represents a huge step forward in the field to cure 
human liver pathologies. Nevertheless, the liver is a very complex 
organ from a structural point of view and highly heterogeneous 
with different cell types participating to develop its function. For 
this reason, there is currently no technology available to grow a 
newly liver that accomplishes all the characteristics to the same 
extent as an original one. Liver engineering tries to solve these 
problems, through the repopulation of a decellularized liver stroma 
scaffold with hepatocytes and other liver cell types, or through 
3D-bioprinting technology with biological materials (Kholodenko 
and Yarygin, 2017). However, these very promising approaches 
have not yet been completely successful as they are very chal-
lenging, although they clearly open a very encouraging landscape. 
Future perspectives
LR is required to guarantee the liver function during processes 
of chronic liver diseases. Furthermore, liver resection is the most 
common approach used by clinicians in secondary/metastatic le-
sions in the liver. For this reason, it is indispensable to continue 
focusing on the molecular mechanisms that orchestrate LR to 
predict and even improve the response of each patient to the 
surgery. Deciphering the enigmas of LR might also contribute to 
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the development of artificial functional livers to be used in patients 
with liver failure. 
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